NEW! Investment Companies Centre

Consort Medical (CSRT)

Sector:

Health Care Equipment & Services

Index:

FTSE Small Cap

Market Cap

£118.37m

Change Today

Price Down-11.00p ()

Share Price

409.00p

Exubera hit hurts profits at Consort Medical

Date: Tuesday 24 Jun 2008

LONDON (ShareCast) - Drug inhaler group firm Consort Medical saw full year profit fall sharply as it felt the impact of Pfizer’s decision to stop marketing its inhalable insulin product Exubera late last year.

Profit before tax from continuing operations fell by 53% to £7.3m due to “a number of special items”, although before theses it rose 1% to £17.6m. Revenue was unchanged at £126.5m.

“We are now on a sound footing with long-term contracts, a blue-chip customer base and good growth prospects from the increased sales of HFA valves, the introduction of dose counters on aerosol drug dispensers and our anaesthesia franchise,” said boss Jon Glenn.

“In addition we continue to look at acquisition opportunities within the healthcare sector.”

In a separate statement, the company said ex-ACTA SpA and Johnson Matthey man Toby Woolrych is its new finance chief. He replaces Glenn who became CEO last December.

The final dividend stays at 12.1p per share.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Consort Medical Market Data

Currency UK Pounds
Share Price 409.00p Price Down
Change Today -11.00p
52 Week High 638.50
52 Week Low 350.00
Volume 6,408
Shares Issued 28.94m
Market Cap £118.37m
Beta 0.16

Performance Indicators

Compare performance with the sector and the market.
Find out more
Key: vs Market vs Sector
Value
90.17% below the market average90.17% below the market average90.17% below the market average90.17% below the market average90.17% below the market average
58.33% below the sector average58.33% below the sector average58.33% below the sector average58.33% below the sector average58.33% below the sector average
Price Trend
43.78% above the market average43.78% above the market average43.78% above the market average43.78% above the market average43.78% above the market average
59.18% above the sector average59.18% above the sector average59.18% above the sector average59.18% above the sector average59.18% above the sector average
Income
37.27% below the market average37.27% below the market average37.27% below the market average37.27% below the market average37.27% below the market average
57.14% above the sector average57.14% above the sector average57.14% above the sector average57.14% above the sector average57.14% above the sector average
Growth
57.02% below the market average57.02% below the market average57.02% below the market average57.02% below the market average57.02% below the market average
95.56% below the sector average95.56% below the sector average95.56% below the sector average95.56% below the sector average95.56% below the sector average
Price Chg 6m
30.98% above the market average30.98% above the market average30.98% above the market average30.98% above the market average30.98% above the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
P/E
11.8% below the market average11.8% below the market average11.8% below the market average11.8% below the market average11.8% below the market average
4.35% above the sector average4.35% above the sector average4.35% above the sector average4.35% above the sector average4.35% above the sector average
PEG
95.58% below the market average95.58% below the market average95.58% below the market average95.58% below the market average95.58% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Dividend Yield
15.38% below the market average15.38% below the market average15.38% below the market average15.38% below the market average15.38% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
EPS Growth
43.62% below the market average43.62% below the market average43.62% below the market average43.62% below the market average43.62% below the market average
44.44% below the sector average44.44% below the sector average44.44% below the sector average44.44% below the sector average44.44% below the sector average
Operating Margin
1.14% above the market average1.14% above the market average1.14% above the market average1.14% above the market average1.14% above the market average
37.78% above the sector average37.78% above the sector average37.78% above the sector average37.78% above the sector average37.78% above the sector average

What The Brokers Say

Strong Buy 1
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Consort Medical Dividends

  Latest Previous
  Final Interim
Ex-Div 24-Sep-08 23-Jan-08
Paid 24-Oct-08 22-Feb-08
Amount 12.10p 7.00p

Trades for 21-Nov-2008

Time Volume / Share Price
16:35 832 @ 409.00p
16:25 254 @ 409.00p
16:24 536 @ 407.25p
16:24 1,053 @ 406.00p
16:23 478 @ 405.00p

Consort Medical Key Personnel

Chair John Robinson
CEO Jonathan Glenn

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).